resourceId,resourceName,resourceType,observationText,observationType,observationPhase,observationTime,observationTimeUnits,doi
a2a0345f-f0ba-4d72-99d7-f9ad2ea77751,Nf14F/Arg681*,['Animal Model'],"The Nf14F/Arg681*; DhhCre mice developed paralysis in one or both hind limbs starting around 4 months of age, with 55.6% exhibiting paralysis by 5 months. They also showed symptoms like lethargy, weight loss, dermatitis, and dehydration.","['Neurological symptoms', 'Body weight']",juvenile,4,months,https://doi.org/10.1242/dmm.025783
a2a0345f-f0ba-4d72-99d7-f9ad2ea77751,Nf14F/Arg681*,['Animal Model'],"The Nf14F/Arg681*; DhhCre model displayed a robust tumor phenotype, with 81.5% of animals developing neurofibromas throughout their lifetime.",['Tumor incidence'],,,,https://doi.org/10.1242/dmm.025783
a2a0345f-f0ba-4d72-99d7-f9ad2ea77751,Nf14F/Arg681*,['Animal Model'],"The Nf14F/Arg681*; DhhCre model showed an earlier onset of paralysis and tumorigenesis at 5 months compared to the previously described Nf131&32F/31&32F; DhhCre model, which exhibited paralysis in 28.6% of animals by 6 months.","['Neurological symptoms', 'Tumor progression']",juvenile,5,months,https://doi.org/10.1242/dmm.025783
a2a0345f-f0ba-4d72-99d7-f9ad2ea77751,Nf14F/Arg681*,['Animal Model'],"By 5 months of age, 54.1% of the Nf14F/4F; DhhCre mice, another model generated in the same study, were paralyzed.",['Neurological symptoms'],juvenile,5,months,https://doi.org/10.1242/dmm.025783
a2a0345f-f0ba-4d72-99d7-f9ad2ea77751,Nf14F/Arg681*,['Animal Model'],"The Nf14F/Arg681* allele stimulated tumorigenesis when placed in context with a loss-of-function allele, as demonstrated by the tumor phenotype in the Nf14F/Arg681*; DhhCre mice.",['Tumor incidence'],,,,https://doi.org/10.1242/dmm.025783
